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1. Introduction
The three mainstays for cancer treatment include surgical removal of tumors, radiation therapy
and chemotherapy, which have led to improved patient survival for certain types of cancer,
but there is still much room for improvement. Cancer is one of the leading causes of death
worldwide and accounted for 7.6 million deaths (13% of all deaths) in 2008 (World Health
Organization, 2012). The 2012 Report to the Nation on the Status of Cancer indicated that there
was a decrease in overall cancer mortality and incidence in the U.S.A. from 1999 to 2008,
particularly for the four major cancer sites: lung, colorectum, breast and prostate [1]. However,
there were increases in the incidence of other types of cancer, including those of the pancreas,
kidney, thyroid and liver, as well as melanoma and adenocarcinoma of the esophagus, from
1999 to 2008.
Over the past decades, the struggle against cancer has led to the discovery of new strategies
to fight this disease and to bring hope to patients. These new strategies include hyperthermia
(also commonly known as thermal therapy or thermotherapy), biological therapies (e.g.
immunotherapy), photodynamic therapy, laser treatment, gene therapy, and inhibitors of
angiogenesis. Most of these strategies still need optimization, and in some cases (e.g. hyper‐
thermia, photodynamic therapy), improved equipment is required. Moreover, a better
understanding of the biological mechanisms involved in their anticancer action would
certainly be beneficial. Hyperthermia is one of the few strategies to be adopted as a promising
therapy among the alternative methods to treat cancer.
Hyperthermia is defined as moderate elevation in temperature. Hyperthermia can either have
a pathological origin, resulting from the fever response of the organism to viral or bacterial
infections, or may occur during exposure to high temperatures as during heat stroke. It is
relatively recent as a clinical procedure, in which body tissues are exposed to elevated
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temperatures in the range of 39°C to 45°C. These high temperatures can damage and kill cancer
cells with minimal injury to normal tissues [2]. During the last two decades, hyperthermia has
been used as an efficient complement to standard cancer treatments such as radiation therapy
and chemotherapy [2,3] (Figure 1). A further advantage is that hyperthermia can eliminate
drug-resistant and radio-resistant tumour cells. Another form of hyperthermia involves very
high temperatures (> 60°C), which can destroy or «cook» tumours by a technique known as
thermal ablation (see review, [4]). The present review will address the therapeutic potential of
moderate hyperthermia (39°C to 45°C).
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Figure 1. Hyperthermia complements standard cancer treatments such as chemotherapy and radiation therapy in de‐
stroying tumour cells.
2. Hyperthermia
2.1. Scientific history
The use of heat to treat disease, including cancer, is a concept that dates back to early Egyptian
times, over 5000 years ago (see review, [5]). Indeed, the Egyptian medical papyrus recounts
an attempt to treat breast cancer with a "heated stick" [6]. Likewise, many Greek doctors, among
them Hippocrates, suggested cauterizing superficial tumours by using heated metal. Many
ancient cultures, including the Roman, Chinese, Indian and Japanese cultures have used this
concept for the treatment of a variety of diseases. During the late 1800s, there were numerous
observations by astute clinicians of spontaneous remissions of cancer in patients suffering from
a variety of infections [7]. Dr. William B. Coley found 47 case reports in which simultaneous
infection seemed to have caused the remission of an incurable neoplastic malignancy (see
review, [8]). In the late 1800s, he used “Coley’s Mixed Toxins” (bacterial pyrogenic toxins) as
a deliberate fever-inducing treatment to control tumor growth [9]. Despite promising obser‐
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vations during several decades, these cancer treatments were difficult to administer in a
controlled manner, and responses were unpredictable [10]. Using a different approach,
Westermark reported the use of localized, non-fever producing heat treatments (42-44°C) by
means of water-circulating cisterns that resulted in the long-term remission of inoperable
cancer of the cervix [11]. As different techniques were developed, such as surgery, radiation
therapy and chemotherapy, further development of hyperthermia for cancer treatment was
put on the back burner. There was a resurgence of interest in the use of hyperthermia in cancer
treatment based on scientific studies initiated in the 1960s and 1970s. A turning point was a
study conducted in transplanted mouse tumors that illustrated novel biological phenomena:
cytotoxicity of hyperthermia was dependent on time and temperature; increased sensitivity
of large versus small tumors to hyperthermia (later attributed to vascular events); heat-induced
thermotolerance of normal and tumor tissue; and hyperthermia-induced sensitization to
radiation [12]. These promising observations led to quantitative experimental studies and a
rapid increase in our understanding of the biological effects of hyperthermia. Furthermore,
they frame the rationale for the clinical use of hyperthermia, and the development of more
effective technologies for the precise application of heat to tumors and for the measurement
of heat distribution in tumors by thermometry.
2.2. Cellular changes
Temperatures in the range of moderate hyperthermia can be non-lethal (39 to 42°C) or lethal
(>42°C). Temperatures above 42°C were shown to kill cancer cells in a time- and temperature-
dependent manner that was measured by the clonogenic cell survival assay [13]. However,
despite numerous studies during at least three decades, which have improved our under‐
standing of hyperthermia biology, the mechanisms involved in heat-induced cytotoxicity are
still ill-defined [14]. Hyperthermia causes many changes in cells and leads to a loss of cellular
homeostasis [15-17]. A key event appears to be protein denaturation and aggregation, which
results in cell cycle arrest, inactivation of protein synthesis, and inhibition of DNA repair
processes [18]. Other cellular effects of hyperthermia include: (1) the inhibition of DNA
synthesis, transcription, RNA processing and translation; (2) increased degradation of
aggregated/misfolded proteins through the proteasomal and lysosomal pathways; (3) disrup‐
tion of the membrane cytoskeleton; (4) metabolic changes (e.g. uncoupling of oxidative
phosphorylation) that lead to decreased levels of ATP; and (5) alterations in membrane
permeability that cause increases in intracellular levels of Na+, H+ and Ca2+ (see reviews, [19,20].
Hyperthermia can cause changes in lipids but these appear to be reversible [21]. The viscosity
of the plasma membrane decreases with increasing temperature [22], and this may be associ‐
ated with altered transport functions of the membrane. Changes in membrane viscosity were
linked to an elevation in the activity of the ATP-dependent sodium-potassium pump [22],
which maintains Na+ and K+ levels across the plasma membrane against a concentration
gradient. During hyperthermia, membrane permeability towards several compounds is
altered, including polyamines, glucose, and anticancer drugs [23-25].
Despite the large number of documented cellular changes, the nature of the critical lesions that
lead to cell death following heat treatment remains unknown. Proteins appear to be the first
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target of hyperthermia in the clinically-relevant temperature range of 39 to 45°C (Figure 2).
The alteration of cellular homeostasis after exposure to hyperthermia entails a certain number
of post-translational modifications such as glycosylation, acylation, phosphorylation, farne‐
lysation and ubiquitination [18,26]. Several studies reported that hyperthermia can cause DNA
fragmentation and the formation of double strand breaks (DBSs) [27,28], which could arise
from the inhibition of DNA repair mechanisms [21]. However, it appears that nuclear protein
damage may be the key factor rather than direct DNA damage itself. Nuclear proteins, in
particular, appear to be very sensitive to hyperthermia and undergo aggregation [21]. Nuclear
protein aggregation has been linked to the inhibition of transcription and DNA replication.
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Figure 2. Hyperthermia-induced cellular changes that could lead to tumour cell death.
Elevated temperatures can increase the rates of biochemical reactions and this would increase
cell metabolism, which should cause increased oxidative stress (Figure 2). Levels of reactive
oxygen species (ROS) were shown to increase after exposure to both lethal (≥42°C) [29-31] and
non-lethal (40°C) temperatures [32,33]. This would arise principally from the increased
generation of ROS such as superoxide and hydrogen peroxide (H2O2), likely as a result of
dysfunction of the mitochondrial respiratory chain. Other potential sources of increased ROS
generation would be increased activity of superoxide-producing enzymes such as NADPH
oxidase and xanthine oxidase at elevated temperatures. Hyperthermia could also increase the
reactivity of these ROS; indeed, the cytotoxicity of hydrogen peroxide was increased at
elevated temperatures (41 to 43°C) compared to the physiological temperature (37°C) [34].
Hyperthermia also inactivated cellular antioxidant defenses against H2O2 such as the pentose
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phosphate pathway [35], which maintains the intracellular antioxidant glutathione in its
reduced form, GSH [36]. An increase in the generation of ROS can cause oxidative damage to
proteins, lipids and nucleic acids. A hyperthermia-induced decrease in tumor growth was
accompanied by an increase in lipid peroxidation in rabbits [37]. Another consequence of
increased ROS generation by hyperthermia is that molecules such as H2O2 can perturb
mitochondrial membrane potential [38]. A temperature-induced increase in cell metabolism
could also cause acidosis of the tumor tissue [39,40].
2.3. Cytotoxicity of hyperthermia
As a consequence of different cellular changes, hyperthermia causes mitotic catastrophe,
permanent G1 arrest and a loss of clonogenic or reproductive cell capacity [21] (Figure 2). Cells
can die by processes such as apoptosis and/or necrosis, which are dependent on the cell type
as well as the temperature and duration of heat exposure [32,41]. Another consequence is that
cells can become sensitized to other cytotoxic modalities such as radiation [16]. Hyperthermia
was reported to cause centrosomal dysfunction and mitotic catastrophe [42], which have been
implicated in thermal radio-sensitization [43]. Hyperthermia (42 to 44°C) has been reported to
cause chromatin condensation and apoptotic DNA fragmentation (formation of DNA ladders)
leading to apoptosis in many different cell types including HeLa cells [44], T lymphocytes
[45,46], HL-60 leukemic cells [47], and mice embryonic fibroblasts [48]. In rats treated with
whole body hyperthermia (41.5°C for 2 h), both the extent and kinetics of hyperthermia-
induced apoptosis differed between two different tumor types (fibrosarcoma and colon
carcinoma) [49]. Additionally, the same study revealed another important advantage; the
induction of apoptosis was higher in tumor tissues in comparison to normal tissues. Most of
the studies that have investigated the mechanisms of heat shock-induced cytotoxicity con‐
cluded that apoptosis is the main form of cell death and proposed the pro-apoptotic effects of
hyperthermia as the potential desired outcome of hyperthermia in cancer therapy.
2.4. Hyperthermia and physiological changes
Several physiological factors including oxygenation, pH and blood flow were shown to play
a role in the sensitivity of cells/tissues to moderate hyperthermia. The intrinsic sensitivity to
heat varies significantly among different cell types. Several studies indicate that cancer cells
are more susceptible to heat injury than normal cells [21,50]. This could be caused, at least in
part, by the differential expression of heat shock proteins (Hsps) and other proteins involved
in the cellular defense system against different stressors, including heat shock. However, there
is no consistency in findings about heat sensitivity between tumor and normal cells [21]. The
sensitivity of cells to heat also varies with phase of the cell cycle, where cells in S phase and
mitosis were reported to be most sensitive [51].
Another  reason  for  the  use  of  hyperthermia  in  cancer  treatment  is  the  fact  that  tumor
tissues  are  poorly  vascularized  in  comparison  to  normal  tissues.  This  may  lead  to  a
differential  heating,  with  higher  temperatures  being achieved in  tumors  compared with
normal  tissue,  where  heat  may  be  dissipated  by  circulating  blood.  Hyperthermia  also
appears to be complementary to other forms of  treatment by being able to destroy tumor
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cells  that  are  relatively  resistant  to  radiation  therapy  or  chemotherapy.  Tumor  cells
located in the hypoxic  centers  of  tumors are relatively resistant  to chemotherapy due to
poor drug delivery.  Several  chemotherapeutic  drugs also require oxygen to generate free
radicals  in order to  cause tumor cytotoxicity.  Further,  most  chemotherapeutic  drugs are
more  effective  against  proliferating  cells.  However,  hypoxia  has  been  shown  to  cause
decreased  proliferation,  which  may  partially  explain  the  reason  for  resistance  of  tumor
cells  to  chemotherapy  [52-54].  Cells  located  in  hypoxic  areas  of  tumors  are  also  resist‐
ant  to  radiation therapy.
Heating of human tumours is heterogeneous. Some areas of the tumour reach cytotoxic
temperatures such as 43 to 45°C, whereas other areas only reach 39 to 42°C. It is more difficult
to heat larger or deep-seated tumours to cytotoxic temperatures that are adequate to cause cell
death or vascular damage.
Tumors are unable to adapt their blood circulation to the effects of high temperatures (≥42°C),
which enables hyperthermia to cut off the supply of nutrients and oxygen, leading to lower
interstitial pH and a collapse in tumor vasculature [55]. These conditions render cells more
susceptible to heat treatment. Indeed, cells at lower (acidic) pH and decreased oxygen tension,
as in the center of tumors, are more sensitive to heat treatment [56,57]. Cells in a nutrient-
deprived environment are also more sensitive to elevated temperatures. This effect appears to
correlate with changes in cellular ATP levels [58]. Cells that were deprived of glucose exhibited
increased sensitivity to the cytotoxicity of hyperthermia [35]. This effect could be linked to a
decrease in antioxidant defenses involving the glutathione redox cycle, since glucose metab‐
olism, through the pentose phosphate pathway, is required for maintaining intracellular levels
of GSH. On the other hand, heating at milder temperatures (e.g. 39° to 42°C) can increase tumor
blood flow, which leads to improved tumor oxygenation [59,60]. This could render tumors
more sensitive to radiation and certain anticancer drugs.
Hyperthermia (≥42°C) has been shown to cause vascular damage in rodent tumours, which
leads to decreased oxygenation and necrosis [61]. Although, the vasculature of human tumours
appears to be more resistant to hyperthermia than that of rodent tissues, hyperthermia has
been shown to cause disturbances in the microcirculation of cancer tissue in human osteosar‐
coma [62].
Milder temperatures in the range of 40 to 41°C appear to be able to stimulate various elements
of the immune system, thus increasing immune surveillance and protecting against tumor
growth (see reviews, [63-65]). The exposure of immune effector cells (e.g. macrophages, T cells,
and natural killer (NK) cells) to mild temperatures has been shown to: (1) enhance the
migration of immune cells to target sites, which could allow better control of infection and
tumor burden; (2) increase the expression of cell surface molecules (e.g. involved in antigen
presentation); (3) increase the release of soluble factors involved in immune effector cell
activity (e.g. pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α),
interleukin-1 (IL-1), IL-6, IL-10, and IL-12; (4) regulate immune cell proliferation; and (5)
increase the cytotoxicity of immune cells against target (tumor) cells.
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2.5. Thermotolerance: The other side of hyperthermia
The exposure of cells to lethal temperatures such as 43 to 45°C during short periods of time,
ranging from 10 to 30 minutes, allows the development of tolerance towards subsequent
exposure to multiple stresses; this phenomenon is termed “thermotolerance” [66,67]. Ther‐
motolerance is an adaptive survival response induced by heat preconditioning whereby cells
become resistant to a subsequent lethal insult such as that triggered by heat shock, reactive
oxygen species (ROS), and environmental stressors including heavy metals [68,69]. If the level
of stress is very low, cells attempt to survive by activating stress responses that protect essential
biochemical processes such as DNA repair, protein folding, and the elimination of damaged
proteins [70]. Once the stress stimulus is removed, cells can recover their normal cellular
function. If the stress continues or is too severe, then the cell will likely die by apoptosis or
necrosis.
The acquisition of thermotolerance is characterized by numerous biochemical and molecular
changes. Thermotolerance is generally associated with the accumulation of Hsps
[19,63,68,71-73]. Hsp expression is regulated by a stress-responsive transcription factor known
as heat shock factor 1 (HSF-1), through its interaction with the heat shock element (HSE) [74].
In addition, changes in the expression of about 50 to 200 other genes, not traditionally
considered Hsps, have been found during or after heat stress (see review, [20]). These include
genes for transcription factors, protein degradation, DNA repair enzymes, metabolic enzymes,
cell cycle arrest, transport and detoxification, and signal transduction. The reason for the
induction of these other cell-protective pathways by heat shock is probably to protect nascent
chain synthesis and folding, prevent protein misfolding and aggregation, and to promote
recovery from stress-induced damage [75]. Proteomic analyses showed a change in the
phosphorylation of 93 proteins between control RIF-1 and their thermotolerant derivatives,
TR-RIF-1 cells [76]. These phosphorylated proteins are responsible for a range of cellular
functions, which include chaperones, ion channels, signal transduction, transcription and
translation, biosynthesis of amino acids, oxidoreduction, energy metabolism, and cell motility
or structure.
The heat shock response is highly conserved in all organisms from yeast to humans, which
suggests that it is important for survival in a stressful environment [74]. In addition to heat,
the heat shock response can be induced by other insults such as oxidative stress, heavy metals,
ethanol, toxins and bacterial infections.
The major classes of Hsps induced by the heat shock response are Hsp90, Hsp70, Hsp60, and
Hsp27. Hsps appear to play an important role in thermotolerance. Many studies suggest a
correlation between the accumulation of Hsp70 and the acquisition of a thermotolerant state
in mammals, amphibians, insects [77-79] and fish [80]. Under conditions of stress, Hsp70s can
prevent the formation of protein aggregates and assist the refolding of aggregated proteins
into their native structures [19]. Other studies have shown that the state of thermotolerance
correlated with an increase in the expression of Hsp110 [81]. Hsp110 is as effective as Hsp70
in preventing protein aggregation, and contributes, along with Hsp70 and Hsp40, to the
refolding of denatured proteins. In addition to their protective role against a subsequent lethal
Hyperthermia: Cancer Treatment and Beyond
http://dx.doi.org/10.5772/55795
263
heat shock, Hsps are known to protect cells against other forms of stress, such as oxidative
stress and radiation [82].
Hsps play an important and yet complex role in the regulation of apoptosis. The specific roles
of different Hsps such as Hsp27, Hsp60, Hsp70 and Hsp90 in the regulation of the mitochon‐
drial and death receptor pathways of apoptosis have been reviewed [82-85]. The induction of
apoptosis through the Fas death receptor can be regulated by Hsp70 and Hsp27 [86,87]. Hsp27
and Hsp70 can regulate the death receptor pathway of apoptosis by preventing t-Bid translo‐
cation to mitochondria, which in turn inhibits cytochrome c release [88, 89]. Hsp90 was shown
to be a negative regulator of caspase-2 activation [90]. Hsp27, Hsp70, and Hsp90 can attenuate
apoptosis upstream of mitochondria [91], as well as interfering with apoptosome formation,
post-mitochondrial events, and caspase activation [92]. Furthermore, Hsp70 and phosphory‐
lated Hsp27 can protect cells against oxidative stress, a potent activator of apoptosis [93,94].
The development of thermotolerance by lethal hyperthermia has been the subject of intensive
studies during the past three decades, whereas thermotolerance induced at mild, fever-range
temperatures has received relatively little attention. Thermotolerance can be developed
following exposure for shorter times (e.g. 30 min) to lethal temperatures (42 to 45°C) [68,71],
or during continuous heating (e.g. 3 to 24 h) at non-lethal temperatures (39 to 41.5°C) [95,96].
The development of thermotolerance by exposure of cells to mild hyperthermia (40°C) for 3
to 24 h led to the accumulation of Hsps 27, 32, 60, 70, 90 and 110 [32,95]. This phenomenon is
of notable importance for fundamental research given that it is a physiological fever-range
temperature and suggests that thermotolerance could protect healthy tissue against stressors
during clinical therapies. The treatment of BALB/c mice in vivo with fever-range whole body
hyperthermia (39.5 to 40°C) for 6h led to increased expression of Hsp70 and Hsp110 in several
mouse tissues [97].
Mild thermotolerance developed at 40°C created an apoptosis-resistant phenotype. The
activation of the mitochondrial pathway of apoptosis by moderate hyperthermia (42 to 43°C)
was attenuated in these thermotolerant cells [44]. Similarly, activation of the death receptor
signaling pathway through the Fas receptor by lethal heat shock (42 to 43°C) was inhibited in
thermotolerant cells [32]. Furthermore, thermotolerance developed at 40°C protected cells
against the induction of apoptosis by oxidative stress (H2O2), mediated through the mitochon‐
drial and death receptor pathways [33,38]. This apoptosis-resistant phenotype could be
conferred by increased levels of both Hsps (Hsps 27, 32, 60, 70, 90, and 110 kDa) and antioxi‐
dants (catalase, manganese superoxide dismutase, glutathione) [32,33]. Mild thermotolerance
also inhibited hyperthermia-induced ROS generation [32], and this could be explained by the
ROS-inhibitory effect of Hsps such as Hsp27 and Hsp70 [93,94].
Hsps play overlapping roles in tumour development and growth by promoting cell prolifer‐
ation and by inhibiting cell death pathways [98]. Hsp70 is a survival protein that is overex‐
pressed in various malignant tumors and its expression correlates with increased cell
proliferation, poor differentiation and poor therapeutic outcome in human breast cancer [99].
The increased expression of Hsp70 in tumors can prevent the activation of caspases and
proteases, and thus abolish apoptotic cell death [98]. Moreover, the increased expression of
Hsps appears to be involved in the acquisition of drug-resistant phenotypes. Several studies
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have reported that Hsp27 may be involved in the development of resistance to chemothera‐
peutic agents such as doxorubicin and cisplatin [100-104].
2.6. Hyperthermia in cancer therapy
The biological rational for the use of hyperthermia in cancer treatment is very strong. Tem‐
peratures of 42.5°C and above are able to kill cancer cells. Findings from in vitro studies
generally indicate that there is no intrinsic difference in heat sensitivity between normal and
tumour cells [105]. However, a tumour selective effect of hyperthermia could occur at higher
temperatures in vivo. In solid tumours, the vascular system is chaotic, which results in regions
with hypoxia and low pH levels, compared to normal tissues. These conditions render cells
more sensitive to the cytotoxic effects of hyperthermia. Therefore, hyperthermia can be
beneficial by causing direct cytotoxicity to tumour cells, in addition to selective destruction of
tumour cells in hypoxic and low pH environments within solid tumours. A further benefit is
that mild hyperthermia can activate certain responses of the immune system, which could also
provide protection against tumour growth [64,106]. In the clinic, hyperthermia has been shown
to be most beneficial when used in combination with radiation therapy and/or chemotherapy.
2.6.1. Hyperthermia in combination with radiotherapy
One of the most promising aspects of hyperthermia in cancer treatment is the ability to
eliminate radiation-resistant tumour cells [see review, 5]. Indeed, this renders hyperthermia
as one of the most effective radiation sensitizers known. The basis for this effect is that
hyperthermia has the ability to kill cells that are under conditions of hypoxia, low pH and that
are in the S-phase of cell division, which are all conditions that render cells resistant to
radiation. The mechanisms responsible for heat-induced radio-sensitization are not entirely
understood, particularly for milder temperatures [21]. For temperatures of 43°C and above,
nuclear protein damage is considered to be a critical event [107]. It was suggested that
hyperthermia interferes with the repair of radiation-induced DNA damage. In support of this
idea, hyperthermia increased the amount of radiation-induced chromosomal aberrations [13,
108]. It was suggested that heat-induced enhancement of chromosomal aberrations could arise
from the inhibition of repair of radiation-induced DNA damage. Hyperthermia could exert its
major effect on radio-sensitization by specifically inhibiting base excision repair of DNA
damage [109,110].
2.6.2. Hyperthermia in combination with chemotherapy
The combined use of regional hyperthermia with systemic chemotherapy has considerable
potential in cancer treatment mainly because localized heat delivery could enhance cytotoxic
activity of anticancer drugs within a defined target region. This may lead to an improved
therapeutic ratio by allowing targeting of chemotherapy, as can be achieved with radiation
therapy. At present, targeted treatment with anticancer drugs can only be accomplished when
they are administered either topically or intra-arterially. There is also evidence to suggest that
the cytotoxic effects of hyperthermia and anticancer drugs may prove to be complementary.
Tumour cells that are located in less well-vascularized regions of a tumour, such as the tumour
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center, may be relatively resistant to systemic chemotherapy because they are exposed to lower
concentrations of drug. The benefit of hyperthermia is that it kills cells most efficiently in the
low pH and hypoxic environment of the tumour core. Furthermore, the temperature achieved
in poorly vascularized regions of the tumour may be higher because of less efficient cooling
by circulating blood. Another potential benefit is that regional hyperthermia at 40–43°C causes
an increase in tumour blood supply [111]. Blood flow and vascular permeability, which are
increased by hyperthermia, are critical factors for drug uptake [112].
Laboratory and in vivo studies have shown that the combined use of hyperthermia and
chemotherapy leads to increased cytotoxic effects of several anticancer drugs such as cisplatin,
anthracyclines, cyclophosphamide, ifosfamide, nitrosoureas, bleomycin, mitomycin, and
nitrogen mustards such as melphalan [16,25,105,113-118]. Optimal heat enhancement of drug
cytotoxicity generally occurs between 40.5°C and 43°C. For drugs such as cisplatin, alkylating
agents, and nitrosoureas, interactions between heat and drug are more than additive (or
synergistic), whereas in other cases, interactions are simply additive [119]. For bleomycin and
Adriamycin, there is a threshold temperature of about 42.5°C to 43°C for enhancement of drug
cytotoxicity. The antimetabolites (e.g. 5-fluorodeoxyuridin and methotrexate) and Vinca
alkaloids or taxanes have independent interactions with hyperthermia. In general, the most
effective heat-drug sequence is drug treatment immediately before heat delivery. The mech‐
anisms of heat-induced enhancement of drug cytotoxicity are not well understood. Possible
mechanisms include improved drug delivery to the tumour due to increased blood perfusion,
increased intracellular uptake of drugs, and increased rates of reaction of drugs with cellular
targets (e.g. increased drug alkylation, increased DNA damage).
2.6.2.1. Resistance to chemotherapeutic agents
One of the major limitations to the successful use of chemotherapy in cancer treatment is the
development of resistance to multiple anticancer drugs. Cross-resistance occurs between
different anticancer agents that have distinct structures and mechanisms of cytotoxicity.
Multidrug resistance (MDR) is characterized by cross-resistance to four classes of commonly
used anticancer drugs such as Vinca alkaloids, anthracyclines, taxanes, and epipodophyllo‐
toxins. Classical MDR was discovered about 35 years ago and was initially related to the
overexpression of the cellular 170-kDa protein P-glycoprotein (Pgp) [120], a member of the
ATP-binding cassette (ABC) transporters. Pgp acts as an ATP-dependent transmembrane
pump. Once anticancer drugs enter cells, they are immediately expulsed out of cells by Pgp.
This results in decreased levels of drugs inside cells, rendering the drugs less effective against
the tumour cells. In addition to Pgp, several other transporter proteins have been implicated
in MDR in human cancer: multidrug resistance-associated protein 1 (MRP1), lung resistance
protein (LRP) and breast cancer resistance protein (BCRP) [121]. MRP1 is a 190-kDa member
of the ABC transporter family of proteins [122]. MRP1-mediated transport requires GSH, as
well as ATP binding and hydrolysis. The overexpression of the protein MRP1 can cause cellular
resistance to several anticancer drugs, including Adriamycin (doxorubicin), epipodophyllo‐
toxins, and Vinca alkaloids such as vincristine, [123]. The substrate spectrum of MRP proteins
also comprises amphiphilic anion conjugates of lipophilic compounds with glutathione (GSH),
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glucuronate, or sulfate [124], as well as cysteinyl leukotriene (LTC4), prostaglandins, and the
anticancer drug methotrexate [125].
Eventually, other distinct mechanisms were also implicated in the MDR phenotype [126].
These mechanisms engage other proteins involved in cellular defenses such as glutathione S-
transferase (GST), an enzyme involved in the cellular detoxification of xenobiotics, which
include certain anticancer drugs, toxins and environmental pollutants that undergo conjuga‐
tion with the antioxidant GSH [127]. Other cellular defenses utilized by the MDR phenotype
include metallothionein, thioredoxin, thymidylate synthase, dihydrofolate reductase, Hsps
and topoisomerase II [126].
Clinical drug resistance appears to be a very complex and multifactorial problem [128] with
multiple mechanisms involved. There is often overlapping substrate specificity between
different drug transporters, and they are commonly co-expressed in many normal tissues and
tumours. Overcoming MDR in cancer treatment presents a formidable challenge [129].
To date, three generations of inhibitors have been used to increase the efficacy of chemotherapy
by inhibiting transporter-mediated drug efflux. However, the development of clinical inhibi‐
tors of ABC transporters as targets for clinical intervention in oncology has been difficult and
new approaches are clearly needed. Clinical drug resistance is a major barrier which, if
overcome, should lead to a significant improvement in patient survival.
2.6.2.2. Hyperthermia and reversal of resistance to chemotherapeutic agents
A beneficial effect of hyperthermia is its ability to reverse resistance to certain chemothera‐
peutic drugs [130]. Hyperthermia increased the cytotoxicity of anticancer drugs such as
methotrexate [131], cisplatin [132], and mitomycin c [133] in cells exhibiting primary drug
resistance. In addition, hyperthermia enhanced the cytotoxicity of melphalan in MDR Chinese
hamster ovary CHRC5 cells that overexpress Pgp [117]. CHRC5 cells are resistant to anticancer
drugs such as colchicine, Vinca alkaloids, Adriamycin, and melphalan [134].
Among the earlier strategies to overcome MDR, Pgp-modulating agents such as cyclosporin
A and verapamil were developed. These chemosensitizers appear to act by decreasing Pgp-
mediated efflux of anticancer drugs from cells, which allows increased accumulation of drugs
to more cytotoxic levels inside cells. However, clinical studies showed that these chemosen‐
sitizers were effective only at toxic doses [128]. Therefore, chemosensitizers with improved
MDR-reversing ability and lower toxicity need to be developed, as well as novel approaches.
Hyperthermia (42 to 43°C) showed beneficial effects by reversing MDR involving Pgp when
melphalan or Adriamycin was combined with Pgp modulators such as cyclosporin A
[135,136]) or verapamil [137,138]. When combined with hyperthermia (43°C), the Pgp modu‐
lator PSC 833 reduced resistance to vinblastine in MDR K562 leukaemia cells and MESSA
leiomyosarcoma cells [139]. Moreover, ultrasound-induced hyperthermia (USHT) increased
Adriamycin cytotoxicity in the MDR human lung adenocarcinoma cell line MV522 [140]. The
alkylating agent melphalan is mainly detoxified through conjugation with GSH, which can be
catalyzed by GST [141]. In addition to overexpression of Pgp, CHRC5 cells also overexpress
the alpha and pi forms of GST, compared to the drug-sensitive AuxB1 cells [142]. Hyperthermia
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was beneficial by enhancing melphalan cytotoxicity in MDR cells when GST was inhibited
using ethacrynic acid [142].
2.6.2.3. Sensitivity of multidrug resistant cells to hyperthermia
Another important advantage for the clinical use of hyperthermia is that MDR cells overex‐
pressing Pgp or MRP1 do not display cross-resistance to heat [25,143]. Indeed, these MDR cells
exhibit equivalent sensitivity to the cytotoxic and apoptosis-inducing effects of hyperthermia
(41-45°C) as their drug-sensitive counterparts. Moreover, drug-resistant sub-clones of human
T-lineage acute lymphoblastic leukaemia (ALL) and acute myeloblastic leukaemia (AML) cells
were as sensitive to hyperthermia as were the drug-sensitive sub-clones [144]. Results from
these studies indicate that, in addition to enhancing drug cytotoxicity in resistant cells,
hyperthermia alone can successfully eliminate MDR cells. Together, these findings clearly
show that hyperthermia could be useful by destroying subpopulations of drug-resistant
tumour cells, which have survived chemotherapy treatments, where the overexpression of Pgp
and MRP1 is involved.
Apoptosis is considered to be a physiological mechanism for the elimination of damaged
and abnormal cells,  such as tumour cells.  One of the hallmark characteristics of tumour
cells is  their ability to evade destruction by apoptosis [145].  The up-regulation of differ‐
ent anti-apoptotic proteins, to provide a survival advantage, has been a frequent explana‐
tion for the resistance of cancer cells to elimination by apoptosis [146].  The induction of
death receptor and mitochondria-mediated signaling pathways of apoptosis by hyperther‐
mia (41 to 43°C) in MDR CHRC5 cells  was compared to drug-sensitive CHO cells [147].
Differences  were found between MDR and drug-sensitive  cells  in  terms of  induction of
apoptosis by hyperthermia. For death receptor-mediated apoptosis,  MDR cells contained
higher  levels  of  the  anti-apoptosis  protein  c-FLIP and they had a  lower  level  of  activa‐
tion of initiator caspase-8 and caspase-10 in response to hyperthermia. In the mitochondria-
mediated  pathway  of  heat-induced  apoptosis,  MDR  cells  showed  higher  mitochondrial
levels  of  the  pro-apoptosis  proteins  Bax  and  tBid,  more  pronounced  mitochondrial
membrane depolarization, and increased levels of the apoptosome protein Apaf-1 (apopto‐
sis protease activating factor 1). The MDR cells appeared to show some resistance to death
receptor-mediated apoptosis [147], in agreement with other studies in leukaemia cells [148,
149], but this resistance appeared to be compensated for by the pro-apoptosis changes in
mitochondrial  apoptosis.  For the execution stage of apoptosis,  the MDR and drug-sensi‐
tive  cells  showed  similar  levels  of  hyperthermia-induced  caspase-3  activation,  as  well
cleavage  of  caspase-3  substrates  poly  (ADP-ribose)  polymerase  (PARP)  and inhibitor  of
caspase-activated DNase (ICAD) [147].  Similar  levels  of  nuclear  chromatin condensation
were  induced  by  hyperthermia,  showing  that  overall,  MDR  cells  are  not  resistant  to
hyperthermia-induced apoptosis compared to the drug-sensitive cells. In summary, MDR
and  drug-sensitive  cells  showed  similar  responses  to  heat  in  terms  of  clonogenic  cell
survival and apoptosis, which indicates that hyperthermia could be a promising strategy
for eradicating MDR tumour cells in the cancer clinic.
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2.7. Hyperthermia in the cancer clinic
2.7.1. Techniques to increase tumour temperatures
In the cancer clinic, hyperthermia is administered by exposing tumour tissues to conductive
heat sources, or non-ionizing radiation (e.g. electromagnetic or ultrasonic fields). Hyperther‐
mia can be applied by either invasive or noninvasive techniques, using externally applied
power. To increase tumour temperatures, hyperthermia can be applied by several different
techniques: local hyperthermia by external or internal energy sources, perfusion hyperthermia
of organs, limbs, or body cavities, and whole body hyperthermia [150].
2.7.1.1. Local hyperthermia
Local hyperthermia entails elevating the temperature of superficial or deep-seated subcuta‐
neous tumours while sparing the surrounding normal tissue, using external, intraluminal or
interstitial heating modalities. The area can be heated externally with high-frequency waves
(e.g. electromagnetic or ultrasound energy) aimed at the tumour from a device outside the
body. To achieve internal heating, one of several types of sterile probes may be used, including
thin heated wires, hollow tubes filled with warm water, implanted microwave antennae, radio-
frequency electrodes and ultrasound. Local hyperthermia has allowed the use of hyperthermia
in conjunction with other modalities of antineoplastic therapy. Local hyperthermia is more
appropriate for the treatment of solid tumours, rather than blood diseases such as leukaemia.
Despite advances in the technology of heating, the non-homogeneous character of the
treatment region (i.e. tissue characteristics and blood flow) can often affect the uniformity of
the heat dispersion in the treated area. This means that it can be difficult to obtain a uniform
regional rise in the temperature that is reproducible [151-155]. Deep regional hyperthermia
combined with chemotherapy, also known as hyperthermic intraperitoneal chemotherapy, is
one of the promising methods for the treatment of prostate carcinoma [156,157] and bladder
cancer [158].
2.7.1.2. Perfusion hyperthermia
This technique involves regional heating through the perfusion of a limb, organ (liver, pelvis,
stomach), or body cavity using heated fluids [159-161]. In perfusion, the patient's blood can be
removed, heated, and then pumped into the region that is to be heated internally. Perfusion
hyperthermia can be applied with or without a cytotoxic drug. When applied to limbs without
a cytotoxic agent, a temperature of about 43°C can be used for about two hours. Lower
temperatures are used when perfusion is performed in combination with cytotoxic agents, to
avoid drug toxicity.
2.7.1.3. Whole body hyperthermia
Externally-induced whole body hyperthermia can be used to treat metastatic cancers that have
spread throughout the body. Whole body hyperthermia can be applied using different
methods and involves heating the patient to a maximum temperature of 41.8 to 42°C. A newer
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approach is to increase the temperature to about 40°C for a longer duration, and use a
combination of mild hyperthermia with cytokines and/or cytotoxic drugs [118].
Many studies are focusing on improving the heating techniques. This is one of the main
challenges that currently limit the clinical use of hyperthermia. Furthermore, improvements
are required to heat effectively the deep-seated tumours that are localized in internal organs.
The use of nanoparticles and the induction heating of magnetic materials that are implanted
into tumors are among the new approaches that are currently being investigated for the
improved application of hyperthermia.
2.7.2. Progress in the cancer clinic
In the cancer clinic, hyperthermia (40 to 44°C) is mainly used as an adjuvant to radiation and
chemotherapy [2,5,16,150]. The major limitations of these conventional cancer treatments are lack
of specificity and normal tissue toxicity. An important advantage of hyperthermia is that the
cytotoxicity of radiotherapy and chemotherapy can be targeted to the tumour volume, thereby
decreasing toxic side effects. The effectiveness of hyperthermia depends on the temperature rise
and the duration of treatment at the elevated temperature. At least 19 randomized studies using
a combination of hyperthermia with radiotherapy, chemotherapy or both, have shown signifi‐
cant improvement in clinical outcome in oncology patients, without a significant increase in side
effects [150]. In all of these studies, the differences were very large. The combination of hyperther‐
mia with radiation resulted in higher (complete) response rates, accompanied by improved local
tumour control rates, better palliative effects, and/or better overall survival rates in many Phase
II clinical trials [162-171]. These studies focused on many types of cancer including tumors of the
head and neck, cervix, rectum, breast, brain, bladder, lung, esophagus, liver, appendix, pros‐
tate, peritoneal lining (mesothelioma), soft-tissue sarcoma and melanoma [2,3,105]. Based on
results from a randomized study [171], radiation combined with hyperthermia was included in
the 2007 Breast Cancer Guidelines for recurrent breast cancer and other localized cancer recurrenc‐
es by the National Comprehensive Cancer Network (NCCN, U.S.A.).
Despite positive phase III trials, the clinical application of hyperthermia remains limited. This
could be partly due to inadequate monitoring of tumour temperatures or thermal dose, during
heat treatments. The temperature distribution throughout a tumour during clinical treatment
is not homogeneous due to variable tissue properties and changes in blood flow [172] To ensure
high quality of treatments, precise tumour temperature measurements and rigorous thermal
dosimetric data are essential. Most hyperthermia centers obtain a sparse number of tempera‐
ture measurements within intraluminal or interstitial catheters [173]. Thermal dose parameters
are dependent on the number of measurement sites and on characteristics such as blood flow
and tumor size [174]. It is eventually hoped that temperature measurements during hyper‐
thermia treatment can be improved by measuring 3D thermal distribution in tumours by
magnetic resonance imaging (MRI) techniques.
In general, hyperthermia treatments are well tolerated by patients. Hyperthermia can cause some
toxicity, including skin burns, but this is usually of limited clinical relevance [166]. Normal tissue
damage and toxicity do not generally occur during 1 hour of treatment with temperatures that are
below 44°C [175]. Nervous and gastrointestinal tissues appear to be most sensitive.
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3. Conclusion
Throughout the past two decades, hyperthermia has been used as a particularly efficient
complement to standard cancer treatments such as radiation therapy and chemotherapy.
Furthermore, considerable progress has been made in our understanding of the biology,
physics and bioengineering involved in hyperthermia. Significant improvement in clinical
outcome has been demonstrated for many different types of tumours, including head and neck,
breast, brain, bladder, cervix, rectum, lung, esophagus, liver, prostate, melanoma and sarcoma
[150]. In Europe, hyperthermia is a standard for the treatment of cervical cancer and some
sarcomas. It is a successful alternative for the treatment of other types of cancer such as brain,
bladder, rectal and esophageal cancer. Moreover, transurethral microwave thermotherapy
(TUMT) has been found to be safe and effective as an alternative to surgery and drug treatment
for chronic urogenital pathologies such as benign prostatic hyperplasia [176]. TUMT is a
minimally invasive therapy that aims to maintain a good quality of life.
In spite of good clinical results, hyperthermia has received little attention [150]. Several
problems associated with the acceptance of this promising treatment modality concern the
limited availability of equipment for heating tumours, the lack of awareness concerning clinical
results, and the lack of financial resources. Hyperthermia is currently under study in many
clinical trials, particularly in Europe, Japan and the US, to improve and better understand this
promising technique. Future areas of challenge and opportunity for hyperthermia include:
improved understanding of thermal biology; improved technologies for delivery and moni‐
toring of heat treatments in patients; successful high-quality clinical trials; and combination of
hyperthermia with emerging cancer therapies [170].
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